Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.  Our goal is to overcome resistance, improve response to treatment and increase overall survival.  We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. 

Biotechnology

Cardiff Oncology

Mark Erlander

Vicki Kelemen

Nancy Sherman

Fairooz F. Kabbinavar

Charles Monahan

Tod Smeal

James Levine

Advisory Team

Finance Team

Leadership Team

Research and Development Team

Teams at Cardiff Oncology

Advisory Team

Finance Team

Leadership Team

Research and Development Team